(Source: Capstone Therapeutics Corporation) TEMPE, Ariz., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp.(OTCQB:CAPS) ('the Company') and LipimetiX Development, Inc., the Company's 60% owned joint venture ('JV') announced today that the Lenders, as defined in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission dated December 15, 2015, informed the Company that the Lenders would not exercise their option to extend the exclusive due diligence period through March 31, 2016 by loaning Capstone a second $1 million, under the terms of the previously-reported Securities Purchase Agreement. The Company believes that this decision by the Lenders is...
↧